Retatrutide and Strength Training

Resistance training during GLP-1 class drug treatment is supported by evidence from semaglutide and tirzepatide studies as a strategy to attenuate lean mass loss. Retatrutide has not been specifically studied with structured resistance training programs, but the principle is likely applicable.

Evidence from GLP-1 Class Drug Studies

Studies of semaglutide and tirzepatide combined with resistance training have shown that exercise attenuates lean mass loss compared to drug treatment alone. A 2023 study (Semaglutide + exercise) found that resistance training preserved significantly more lean mass during weight loss. These findings are likely applicable to retatrutide given the shared GLP-1 mechanism, but direct evidence is lacking.

Practical Considerations

Retatrutide significantly reduces appetite, which can reduce overall caloric intake including protein. During resistance training, adequate protein intake is essential for muscle protein synthesis. People on retatrutide should be deliberate about protein intake to support training adaptations. Consult a physician or registered dietitian for individualized guidance.